Lindsay Anne Magura Rein
Assistant Professor of Medicine
Current Appointments & Affiliations
- Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2021
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2016
Contact Information
- Dept of Medicine, Box 31079 DUMC, Durham, NC 27710
-
lindsay.magura@duke.edu
(919) 684-8111
- Background
-
Education, Training, & Certifications
- Resident, Internal Medicine, Duke University School of Medicine 2008 - 2011
- M.D., University of North Dakota, School of Medicine and Health Sciences 2008
-
Previous Appointments & Affiliations
- Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2018 - 2020
- Medical Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2014 - 2017
- Research
-
Selected Grants
- MCW:Txt Free Remission After Combo Therapy with Rux Plus Tyrosine Kinase Inhibition in CP-CML Who Relapsed after TKI Discontination awarded by Medical College of Wisconsin 2022 - 2027
- PTG-300-11 awarded by Protagonist Therapeutics Inc. 2022 - 2027
- CGT9486-21-202 awarded by Cogent Biosciences, Inc 2022 - 2027
- Protocol GRN163LMYF3001 awarded by Geron Corporation 2022 - 2027
- Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib awarded by Incyte Corporation 2021 - 2026
- Randomized, Double-Blind, Placebo-Controlled Ph2 BLU-285 in Indolent and Smoldering Systemic awarded by Blueprint Medicines Corporation 2021 - 2026
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K? Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis awarded by Incyte Corporation 2021 - 2026
- A Phase I Trial of Incorporating Natural Killer (K-NK) cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy awarded by Kiadis Pharma 2021 - 2026
- A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia awarded by Imago BioSciences 2020 - 2025
- Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis awarded by CTI Biopharma Corp. 2020 - 2025
- Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ss) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis awarded by Actuate Therapeutics 2020 - 2025
- BBI Ph1 TP-3654 and Ruxolitinb in patients with Intermediate and High Risk Myelofibrosis awarded by Sumitomo Dainippon Pharma Co. 2020 - 2025
- Targeting beta-arrestins in myeloid malignancies awarded by Department of Defense 2020 - 2023
- COVID-19 Phase 3 Assess Efficacy of Ruxolitinib awarded by Incyte Corporation 2020 - 2021
- A Phase 1b, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis awarded by Novartis Pharmaceuticals Corporation 2020 - 2021
- Targeting Beta-arrestins in myeloid malignancies awarded by American Society of Hematology 2018 - 2020
- An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination with Low-Dose Ruxolitinib or Itacitinib Alone following Ruxolitinib in Subjects with Myelofibrosis awarded by Incyte Corporation 2018 - 2020
- B-arrestin2 and the disease course of chronic myeloid leukemia (CML) awarded by American Society of Hematology 2014 - 2015
-
External Relationships
- AbbVie Pharmaceuticals
- Blueprint Medicines
- CTI Bio
- Celgene Corporation
- Clinical Care Options
- Novartis
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Lin, Chenyu, Mitchell E. Horwitz, and Lindsay A. M. Rein. “Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.” Int J Mol Sci 24, no. 1 (December 22, 2022). https://doi.org/10.3390/ijms24010204.Full Text Link to Item
-
Rein, Lindsay, Karel Calero, Ronak Shah, Charles Ojielo, Kristin M. Hudock, Saba Lodhi, Farid Sadaka, et al. “Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.” Crit Care Med 50, no. 12 (December 1, 2022): 1701–13. https://doi.org/10.1097/CCM.0000000000005682.Full Text Link to Item
-
El Chaer, Firas, James McCloskey, Lindsay A. M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, et al. “Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy.” Blood 140, no. Supplement 1 (November 15, 2022): 594–95. https://doi.org/10.1182/blood-2022-159086.Full Text
-
Wolfe, Heather R., Mitchell E. Horwitz, and Lindsay A. M. Rein. “The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis.” J Pers Med 12, no. 4 (April 2, 2022). https://doi.org/10.3390/jpm12040571.Full Text Link to Item
-
Wolfe, Heather R., and Lindsay A. M. Rein. “The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML).” Curr Hematol Malig Rep 16, no. 5 (October 2021): 448–54. https://doi.org/10.1007/s11899-021-00655-z.Full Text Link to Item
-
Rein, Lindsay, and David A. Rizzieri. “A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy.” Transplantation and Cellular Therapy 27, no. 3 (March 2021): S161–S161. https://doi.org/10.1016/s2666-6367(21)00198-6.Full Text
-
Rein, Lindsay A. M., and David A. Rizzieri. “A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy.” Blood 136, no. Supplement 1 (November 5, 2020): 5–5. https://doi.org/10.1182/blood-2020-142062.Full Text
-
Gerds, Aaron T., Jason Gotlib, Prithviraj Bose, Michael W. Deininger, Andrew Dunbar, Amro Elshoury, Tracy I. George, et al. “Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 9 (September 2020): 1248–69. https://doi.org/10.6004/jnccn.2020.0042.Full Text Link to Item
-
Luedke, Catherine, and Lindsay Rein. “Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2.” Blood 136, no. 9 (August 27, 2020): 1113–1113. https://doi.org/10.1182/blood.2019004410.Full Text
-
Paul, Barry, Yue Zhao, Gavin Loitsch, Daniel Feinberg, Parker Mathews, Ian Barak, Megan Dupuis, et al. “The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.” Cancer Med 9, no. 16 (August 2020): 5869–80. https://doi.org/10.1002/cam4.3265.Full Text Link to Item
-
Gotlib, Jason, Aaron T. Gerds, Prithviraj Bose, Mariana C. Castells, Michael W. Deininger, Ivana Gojo, Krishna Gundabolu, et al. “Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 16, no. 12 (December 2018): 1500–1537. https://doi.org/10.6004/jnccn.2018.0088.Full Text Link to Item
-
Rein, Lindsay A. M., Haeyoon Yang, and Nelson J. Chao. “Applications of Gene Editing Technologies to Cellular Therapies.” Biol Blood Marrow Transplant 24, no. 8 (August 2018): 1537–45. https://doi.org/10.1016/j.bbmt.2018.03.021.Full Text Link to Item
-
Rein, Lindsay Am, James W. Wisler, Jihee Kim, Barbara Theriot, LiYin Huang, Trevor Price, Haeyoon Yang, et al. “β-Arrestin2 mediates progression of murine primary myelofibrosis.” Jci Insight 2, no. 24 (December 21, 2017). https://doi.org/10.1172/jci.insight.98094.Full Text Link to Item
-
Mesa, Ruben A., Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, et al. “NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.” J Natl Compr Canc Netw 15, no. 10 (October 2017): 1193–1207. https://doi.org/10.6004/jnccn.2017.0157.Full Text Link to Item
-
Rein, Lindsay A. M., and David A. Rizzieri. “Clinical potential of elacytarabine in patients with acute myeloid leukemia.” Ther Adv Hematol 5, no. 6 (December 2014): 211–20. https://doi.org/10.1177/2040620714552615.Full Text Link to Item
-
Rein, Lindsay A. M., and Nelson J. Chao. “WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.” Expert Opin Investig Drugs 23, no. 3 (March 2014): 417–26. https://doi.org/10.1517/13543784.2014.889114.Full Text Link to Item
-
Rein, Lindsay Am, Anthony D. Sung, and David A. Rizzieri. “New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.” Int J Hematol Oncol 2, no. 1 (February 2013). https://doi.org/10.2217/ijh.13.4.Full Text Link to Item
-
Friedman, Daphne R., Lindsay A. Magura, Holly A. C. Warren, Jeremy D. Harrison, Louis F. Diehl, and J Brice Weinberg. “Statin use and need for therapy in chronic lymphocytic leukemia.” Leuk Lymphoma 51, no. 12 (December 2010): 2295–98. https://doi.org/10.3109/10428194.2010.520050.Full Text Link to Item
-
Magura, Lindsay, Richelle Blanchard, Brian Hope, James R. Beal, Gary G. Schwartz, and Abe E. Sahmoun. “Hypercholesterolemia and prostate cancer: a hospital-based case-control study.” Cancer Causes Control 19, no. 10 (December 2008): 1259–66. https://doi.org/10.1007/s10552-008-9197-7.Full Text Link to Item
-
-
Conference Papers
-
Harrison, Claire, Vikas Gupta, Abdulraheem Yacoub, Salman Fazal, Carole Miller, Srdan Verstovsek, Ruben Mesa, et al. “Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib.” In British Journal of Haematology, 193:110–11, 2021.Link to Item
-
Gupta, Vikas, Abdulraheem Yacoub, Salman Fazal, Carole Miller, Srdan Verstovsek, Ruben Mesa, Claire Harrison, et al. “Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib.” In Clinical Lymphoma Myeloma & Leukemia, 20:S331–32, 2020.Link to Item
-
Sung, Anthony D., Carlos M. de Castro, Thomas W. LeBlanc, Gwynn D. Long, Donna B. Adams, Danielle M. Brander, Sandeep Dave, et al. “Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.Link to Item
-
Rein, Lindsay A. M., James W. Wisler, Barbara S. Theriot, Li-Yin Huang, Richard T. Premont, and Robert J. Lefkowitz. “beta-arrestin2 Is Necessary for Development of MPLW515L Mutant Primary Myelofibrosis.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.Link to Item
-
Rein, Lindsay A. M., Minyong Chen, Barbara S. Theriot, James W. Wisler, Laura M. Wingler, Richard T. Premont, Wei Chen, Julia K. L. Walker, and Robert J. Lefkowitz. “Targeting β-arrestin2 Enhances Survival in a Murine Model of Chronic Myeloid Leukemia.” In Blood, 122:857–857. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.857.857.Full Text
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.